• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » High risk of ignoring individual patterns of medication adherence

High risk of ignoring individual patterns of medication adherence

March 15, 2016
CenterWatch Staff

Hundreds of millions of dollars are spent ensuring operational quality in clinical trials includ­ing site compliance, accuracy of data entry and enrollment targets. Meanwhile, one of the most vul­nerable aspects of the process—whether or not study participants are taking the investigation com­pound—receives surprisingly scant attention.

Medication nonadherence is well documented in real-world settings. Approximately half of all patients do not take their medication as prescribed, leading to hundreds of billions of dollars in unnecessary healthcare costs. Less publicized is the extent of drug nonadherence in research settings. Clinical trial pro­tocols are built around the assump­tion that study participants will be 80% adherent or better. A trial’s statistical power and the number of participants needed is based on this assumption. Yet adherence in clini­cal trials ranges from 43% to 87%, a far cry from the expected 80%.

The result of this disconnect be­tween what is expected and what ac­tually happens can have devastating consequences. Poor adherence can under-power a trial and drown out an efficacy signal of what might have been an effective and successful drug, resulting in an incorrect no-go decision to proceed to the next phase. Even if average adherence is at 80% or above for all participants, this still remains an average. Two participants with 60% and 100% ad­herence respectively would average out to the required 80%, however, not knowing exact dosing patterns of each participant will preclude a true understanding of the drug’s ef­ficacy and safety profile.

The recent confluence of inexpen­sive mobile technology equipped with sufficient processing power to handle complex artificial intel­ligence applications is allowing us to collect and analyze data that has never been measured before. The knowledge obtained through AI, such as real-time confirmation of drug ingestion, is going to open up new possibilities and accelerate the pace in drug discovery.

 

Written by Guest Writer Adam Hanina. Hanina is CEO of AiCure, which uses artificial intelligence to visually confirm medication ingestion on smartphones. The AI platform is entirely software-based and ensures that the right patient is taking the right medication at the right time. Mr. Hanina has acted as a subject-matter expert on medication adherence technologies for the NIH. He is an advocate for the use of technology as a means to improve the conduct of clinical trials. For more information, please visit:
www.aicure.com or tweet @AiCureMed

This article was reprinted from Volume 23, Issue 03, of The CenterWatch Monthly, an industry leading publication providing hard-hitting, authoritative business and financial coverage of the clinical research space. The Action Items section features short columns  focusing on actionable or how-to advice from clinical trial professionals. To submit an Action Item, please contact editorial@centerwatch.com. Subscribe >>

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing